Press releases
- Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Revance to Participate in Upcoming Investor Conferences
- Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
- Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
- Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
More ▼
Key statistics
As of last trade, Revance Therapeutics Inc (RTI:DUS) traded at 3.92, 83.18% above the 52 week low of 2.14 set on Jun 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.92 |
---|---|
High | 3.92 |
Low | 3.92 |
Bid | 3.52 |
Offer | 3.62 |
Previous close | 3.60 |
Average volume | 1.17k |
---|---|
Shares outstanding | 104.45m |
Free float | 94.91m |
P/E (TTM) | -- |
Market cap | 453.31m USD |
EPS (TTM) | -3.61 USD |
Data delayed at least 15 minutes, as of Jul 24 2024 07:11 BST.
More ▼